Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 6/20 | 0.56 |
| ▸ | EGLN1 | Q9GZT9 | 3/20 | 0.47 |
| ▸ | CTSA | P10619 | 1/20 | 0.47 |
| ▸ | USP30 | Q70CQ3 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.43 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29929320 | 0.84 | HIF1A (0.55) | HIF1ACTSA | |
| SCHEMBL71034 | 0.84 | HIF1A (0.55) | HIF1ACTSA | |
| Hydrochloric Acid SCHEMBL28470042 | 0.82 | HIF1A (0.54) | HIF1ACTSA | |
| SCHEMBL12723128 | 0.81 | HIF1A (0.61) | HIF1AEGLN1CTSAUSP30 | |
| SCHEMBL11047806 | 0.81 | HIF1A (0.53) | HIF1AEGLN1CTSAUSP30MEN1 | |
| Ethylene SCHEMBL29031104 | 0.81 | HIF1A (0.53) | HIF1ACTSA | |
| SCHEMBL6264166 | 0.81 | MAPT (0.53) | HIF1AEGLN1CTSAUSP30MEN1 | |
| SCHEMBL2927582 | 0.81 | HIF1A (0.53) | HIF1AKMT2A | |
| SCHEMBL18135107 | 0.80 | HIF1A (0.60) | HIF1AEGLN1CTSAUSP30 | |
| SCHEMBL27828405 | 0.80 | RAB9A (0.68) | HIF1AKCNQ3KCNQ2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111902419-B | Novel nucleosides or nucleotide derivatives and use thereof | ST制药株式会社 | 2023-11-24 | — | — | CN | disclosed |
| US-11655268-B2 | Nucleoside or nucleotide derivatives, and uses thereof | ST PHARM CO., LTD. (KR) | 2023-05-23 | — | — | US | disclosed |
| US-20210040135-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | ST PHARM CO., LTD. (KR) | 2021-02-11 | — | — | US | disclosed |
| EP-3744726-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | ST Pharm Co., Ltd. (KR) | 2020-12-02 | — | — | EP | disclosed |
| CN-111902419-A | Novel nucleoside or nucleotide derivatives and use thereof | ST制药株式会社 | 2020-11-06 | — | — | CN | disclosed |
| US-20200125564-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2020-04-23 | — | — | US | disclosed |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2020-01-28 | — | — | US | disclosed |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2018-07-12 | — | — | US | disclosed |
| US-9926325-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | OGEDA SA (BE) | 2018-03-27 | — | — | US | disclosed |
| EP-3176171-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-06-07 | — | — | EP | disclosed |
| EP-2552920-B1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2017-03-15 | — | — | EP | disclosed |
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | OGEDA SA (BE) | 2014-12-18 | — | — | US | disclosed |
| US-8871761-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | EUROSCREEN S.A. (BE) | 2014-10-28 | — | — | US | disclosed |
| EP-2552920-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | Euroscreen S.A. (BE) | 2013-02-06 | — | — | EP | disclosed |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2013-01-24 | — | — | US | disclosed |
| WO-2011121137-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | EUROSCREEN S.A. (BE) | 2011-10-06 | — | — | WO | disclosed |
| EP-1102535-A4 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORP (US) | 2004-09-29 | — | — | EP | disclosed |
| US-6399656-B1 | USING A BENZOPYRAN-3-CARBOXAMIDE COMPOUND | SMITHKLINE BEECHAM CORPORATION | 2002-06-04 | — | — | US | disclosed |
| EP-1102535-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000006085-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2000-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371218-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HIF1A 3720/4885EGLN1 4185/4885CTSA 809/4885 |
| US-20180194772-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HIF1A 3720/4885EGLN1 4185/4885CTSA 809/4885 |
| US-20210040135-A1 | NOVEL NUCLEOSIDE OR NUCLEOTIDE DERIVATIVES, AND USES THEREOF | PNP, SLC28A1, NT5C3B | HIF1A 4070/4885EGLN1 4267/4885CTSA 1285/4885 |
| US-11655268-B2 | Nucleoside or nucleotide derivatives, and uses thereof | PNP, SLC28A1, NT5C3B | HIF1A 3807/4885EGLN1 4263/4885CTSA 1486/4885 |
| US-20130023530-A1 | NOVEL NK-3 RECEPTOR SELECTIVE ANTAGONIST COMPOUNDS, PHARMACEUTICAL COMPOSITION AND METHODS FOR USE IN NK-3 RECEPTORS MEDIATED DISORDERS | ACKR3, BDKRB2, GPR3 | HIF1A 3720/4885EGLN1 4185/4885CTSA 809/4885 |
| US-10544150-B2 | NK-3 receptor selective antagonist compounds, pharmaceutical composition and methods for use in NK-3 receptors mediated disorders | BDKRB2, ACKR3, KLRK1 | HIF1A 3890/4885EGLN1 4436/4885CTSA 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.